The continuing resolution that passed last night does extend telehealth flexibilities.
The temporary spending bill that the House and Senate approved last night will keep the federal government operating through March and provide $100 billion in disaster relief and aid to farmers does not include measures to regulate pharmacy benefit managers (PBM) and other healthcare-related provisions.
A week of political drama and President-elect Donald Trump and Elon Musk using their social media platforms to kill a much larger bill of more than 1,500 pages ended shortly after Friday midnight with the Senate voting 85-11 in favor of the stopgap spending measure. Earlier, the House voted 366-34 in favor of the spending legislation averted a federal government shutdown just before the winter holidays.
The scaled-back version of the spending package, called a continuing resolution, includes extension of more liberal rules for telehealth that were adopted during the COVID-19 public health emergency and set the stage for telehealth becoming a common way to patients to interact with clinicians.
Congress has been investigating and debating new rules and regulations for PBM industry for years. On Wednesday it looked like that tortuous process would finally result in legislation and new ground rules for a segment of the healthcare industry that has come under increasing scrutiny.
The PBM-related provisions in the first version of the continuing resolution included a ban on spread pricing in the Medicaid program, delinking of PBM remuneration from drug prices in the Medicare Part D program and transparency and rules governing PBM remuneration in the commercial market.
The Pharmaceutical Care Management Association (PCMA), the trade group for the large established PBMs, was ardently opposed to those provisions while Transparency-Rx,a new group of smaller PBMs that are vying for business with what they say are more transparent business practices, was just as strongly in favor of them.
The large spending bill, which had many unrelated provisions tacked on to it to satisfy dozens of different constituencies and interest groups and win bipartisan support, seemed headed for passage until Musk and then Trump attacked it as ungainly and expensive and an example of the politics-as-usual that they say they want to disrupt. Democrats defended it as a negotiated compromise and important vehicle for addressing important needs. On Thursday, the House voted down a second, stripped-down version of the continuing resolution that jettisoned the PBM and many other provisions. That version, however, included a lifting of the debt ceiling favored by Trump that some Republicans and Democrats opposed.
The third, successful version of the continuing resolution that passed last night was also a vastly reduced version of the first continuing resolution but didn’t have debt ceiling provisions.
On X, the social media platform that he owns, Musk congratulated House Speaker Mike Johnson yesterday. “Your actions turned a bill that weighed pounds into a bill that weighed ounces.”
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More